SlideShare a Scribd company logo
Dr. Zulcaif Ahmad
Ph.D. Scholar (Pharmaceutics)
MPhil Pharmaceutics (Gold Medalist), Pharm.D (Gold Medalist)
Magnetically Modulated Drug Delivery
System (MMDDS)
 Drug targeting is the delivery of the drugs to receptors or organs or
any specific part of the body to which one wishes to deliver
exclusively.
 Magnetic Drug Targeting means the specific delivery of therapeutic
agents to their desired target area using magnetic field, e.g. tumors
by using magnetic nanoparticle (ferrofluids) bound to these agents
and an external magnetic field which is focused on the tumor.
 Magnetic fields are believed to be harmless to
biological systems and adaptable to any part of the body.
 Magnetic particles composed of magnetite (rock mineral and one of
the main iron ores, with the chemical formula Fe3O4, Nickle, iron,
cobolt and iron-boron etc) are well tolerated by body.
Principles of magnetic targeting
 In this technique, drug is bound to a magnetic compound ,
injected into a patient’s blood stream, and stopped with a
powerful magnetic field in the target area.
 Depending upon the type of drug , it is then slowly released
from the magnetic carriers. Very high concentrations of
chemotherapeutic or radiological agents can be achieved near
the target site ,without any toxic effects to surrounding tissue or
to the whole body.
Principles of magnetic targeting
MMDDS
Drug / Carrier
Target Tissue
RES Organs (Liver,
Spleen, Bone marrow)
Mag.Drug/Carrier
Phagocytosis
Target Tissue
Mechanism
 Magnetic drug transport technique is based on the fact that the
drug can be either encapsulated into a magnetic microsphere
(or nanosphere) or conjugated on the surface of the
micro/nanosphere.
 When the magnetic carrier is intravenously administered, the
accumulation take place within area to which the magnetic
field is applied.
 An external permanent magnetic field is applied on desired
area to guide and concentrate the drugs.
 Accumulation of the carrier at the target site allows them to
deliver the drug locally.
Physiological parameters that affect the MMDDS
 Efficiency of accumulation of magnetic carrier depends on
physiological parameters
 Particle size
 Surface characteristic
 Field strength
 Blood flow rate etc
• This technique give us a major advantage that target the specific
area and reduce the systemic distribution of drugs and result in
effective treatment at lower doses.
Concept of Magnetic Drug Targeting
Magnet design: F= M ΔH, F is the force on particles, M is magnetic movement of
particles, ΔH is magnetic field gradient.
Magnetically Modulated Microcarriers
 Following are the various magnetic carriers
I. Magnetic microsphere
II. Magnetic liposomes
III. Magnetic nanoparticles
IV. Magnetic Resealed Erythrocytes
V. Magnetic Emulsion
VI. Biomodulators
VII. Magnetic neutrophils
I) Magnetic Microsphere
 Magnetic microspheres are supramolecular particles that are
small enough to circulate through capillaries without producing
embolic occlusion (<4 μm)
 The loaded microspheres are introduced into a blood vessel, and
in as little as half an hour, they gather at the target site by
magnetic field of 0.5 – 0.8 tesla (T).
 Magnetic microspheres were prepared by mainly two methods
1. Phase separation emulsion polymerization
2. Continuous solvent evaporation
1) Phase Separation emulsion
Polymerization
Fig 1.1. Formation of Magnetic Microsphere
Dicloromethane
(CH2Cl2) +
Hexadecane
(C16H34)
2) Continuous Phase Evaporation
Fig 1.2. Formation of Magnetic Microsphere
Evaluation Parameters
 Particle size analysis
 Surface topography
 Texture
 SEM
 Drug entrapment efficiency
 Percent magnetite content
 In-vitro magnetic responsiveness
 Drug release
II) Magnetic liposomes
 Liposomes are simple microscopic vesicles in which lipid bilayer
structures are present with an aqueous volume entirely enclosed
by a membrane, composed of lipid molecule.
 There are a number of components present in liposomes with
phospholipids and cholesterol being the main ingredients but in
case of magneto liposomes magnetite is one of the components
of the liposomes.
Method of Preparation:
 Generally these are magnetic carrier which can be prepared by
entrapment of Ferro fluid within core of liposomes
 Magneto liposome can also be produced by covalent attachment
of ligands to the surface of the vehicles or by incorporation of
target lipids in the matrix of structural phospholipids
 Size range (80to 300 nm)
Fig 1.3. Magnetic Liposomes
DOX = Doxorubicin (Anti-cancer drug)
III) Magnetic nanoparticles
 Magnetic nanoparticles (MNPs) possess unique magnetic
properties and the ability to function at the cellular and
molecular level of biological interactions making them an
attractive platform.
 MNPs are now being developed for applications in the
detection, diagnosis, and treatment of malignant tumors,
cardiovascular disease, and neurological disease.
Method of Preparation:
 They can be synthesized using different methods like co-
precipitation, thermal decomposition and micro emulsion
method.
 Size range (1 to 100 nm).
Co-precipitation
 The simultaneous precipitation of more than one
compound from a solution.
 Reactions involve the simultaneous occurrence of
nucleation, growth, coarsening, and/or agglomeration
processes.
Fig 1.4. Magnetic nanoparticle
IV) Magnetic Resealed Erythrocytes
 Erythrocyte load with drug and magnetite using press well technique
 Resealed erythrocytes have various advantages as drug carriers such as it is
a) biodegradable
b) Biocompatible
c) Large quantity of variety of material can be encapsulated within small volume of cell.
d) It can be utilized for organ targeting.
Method of Preparation:
 Magnetic resealed erythrocytes contains ferrofluides (magnetite) along with loaded
drugs (Ibuprofen) within the cell.
 The technique is based upon initial controlled swelling in a hypotonic buffered
solution. This mixture is centrifuged. The supernatant is discarded and the cell
fraction is brought to the lysis point by adding 100-120 liters portions of an aqueous
solution of the drug to be encapsulated. The mixture is centrifuged. The tonicity of
a cell mixture is restored at the lysis point by adding a calculated amount of
hypertonic buffer (also called isotonic treatment).
 Then, the cell suspension is incubated at 37oC to reanneal the resealed erythrocytes.
Fig 1.6. Prevention of Arterial
Thrombosis by Aspirin loaded
Magnetic Resealed Erythrocytes.
Fig 1.5. Magnetic resealed erythrocyte formation
V) Magnetic Emulsion
 Magnetic emulsion was also tried as drug carrier for
chemotherapeutic agents.
Method of Preparation:
 The emulsion is magnetically responsive oil in water type of
emulsion bearing a chemotherapeutic agent which could be
selectively localized by applying an external magnetic field to
specific target site.
 Akimoto and Morimoto prepared magnetic emulsion by
utilizing ethyl oleate based magnetic fluid as the dispersed
phase, Casein solution as the continuous phase and anticancer
agent, Methyl CCNU (Semustine) trapped in the oily dispersed
phase as an active chemotherapeutic agent.
 Methyl CCNU is a chloroethylnitrosourea
Fig 1.7. Magnetic Emulsion
VI) Biomodulators
 Biological response modifiers (BMRs) alter host, tumor as well
as microbial responses in four ways
1. Augmentation of host effectors mechanisms directed against
tumor cells or micro organisms.
2. Decrease in host response that interferes with tumor
resistance by a quantitative increase in endogenous effector
resistance by an increase in endogenous effector molecules or
redirecting their sites and duration of action.
3. Augmentation of tumor sensitivity to host cells by
dedifferentiating tumor cells.
4. Increase in host tolerance of conventional cancer treatment.
 There are basically two types of agents; Indirect and direct
agents.
 Indirect agents:
 Include white cell chemo attractant, interleukins (1 to 4)
and immunomodulator such as interferon(α , β and γ).
 Direct agents:
 Antibodies, lymphotoxin and tumor necrosis factor (TNF,
also called Cachetin).
VII) Magnetic neutrophils
 Indirect approach of targeting white cells by chemo
attraction fails. Even though failure of chemotaxis is not
observed in all patients, such conditions are life
threatening.
 Making neutrophils ingest magnetite base system ought to
be developed, so that the sites of severe infection can be
selectively approached for therapy.
APPLICATIONS
 Some of the application of magnetically modulated drug
targeting especially tumor targeting along with some other
application are
1. Magnetic systems for the therapy of diseases.
2. Magnetic delivery of chemotherapeutic drugs to liver tumors.
3. Magnetic targeting of radioactivity.
4. Treatment of tumors with magnetically induced hyperthermia.
5. Other magnetic targeting applications.
6. Magnetic control of pharmacokinetic parameters and drug
release.
 Magnetic systems for the diagnosis of diseases.
 Magnetic systems for magnetic cell separation.
Magnetically Modulated DDS
CONCLUSION
 Magnetic Drug targeting is efficient & novel approach
of drug targeting.
 Larger amount of freely circulating drug can be
replaced by smaller amount of magnetically targeted
drug.
 It is a challenging area for future research in the drug
targeting.
 More researches, long term toxicity study, and
characterization will ensure the improvement of
magnetic drug delivery system.
Magnetically Modulated DDS

More Related Content

PDF
Common problems associated with Oral cavity
PPTX
Concept of clearance & factors affecting renal excretion
PPTX
Distribution
PPTX
INSTRUMENTATION OF UV-VISIBLE SPECTROPHOTOMETRY
PPTX
Barriers to Protein and peptide drug delivery system
PPTX
MAGNETICALLY MODULATED DRUG DELIVERY SYSTEMS
PPT
Protein drug binding
Common problems associated with Oral cavity
Concept of clearance & factors affecting renal excretion
Distribution
INSTRUMENTATION OF UV-VISIBLE SPECTROPHOTOMETRY
Barriers to Protein and peptide drug delivery system
MAGNETICALLY MODULATED DRUG DELIVERY SYSTEMS
Protein drug binding

What's hot (20)

PDF
Pulmonary Drug Delivery System (PDDS)
PPTX
Biological process involved in drug targetting
PPTX
PPTX
Targeted drug delivery system
PPTX
Targeted drug delivery system
PPT
Nasal & Pulmonary Drug Delivery System
PPTX
Targeted drug delivery systems
PDF
Nano particle Preparation and Evaluation
PPTX
OSMOTIC DRUG DELIVERY SYSTEM
PPTX
Implantable drug delivery system
PPT
Bioadhesive drug delivery system
PPTX
Mucoadhesive drug delivery system
PPTX
Approaches to Targeted Delivery of Drugs
PPTX
Tumour targeting and Brain specific drug delivery
PPTX
Niosomes
PDF
Polymers - Mucoadhesive Drug Delivery
PPTX
Nanoparticles, types, preparation and evaluation ppt.pptx
PPTX
microspheres types , preparation and evaluation
PPTX
Transdermal Drug Delivery System SG.pptx
Pulmonary Drug Delivery System (PDDS)
Biological process involved in drug targetting
Targeted drug delivery system
Targeted drug delivery system
Nasal & Pulmonary Drug Delivery System
Targeted drug delivery systems
Nano particle Preparation and Evaluation
OSMOTIC DRUG DELIVERY SYSTEM
Implantable drug delivery system
Bioadhesive drug delivery system
Mucoadhesive drug delivery system
Approaches to Targeted Delivery of Drugs
Tumour targeting and Brain specific drug delivery
Niosomes
Polymers - Mucoadhesive Drug Delivery
Nanoparticles, types, preparation and evaluation ppt.pptx
microspheres types , preparation and evaluation
Transdermal Drug Delivery System SG.pptx
Ad

Similar to Magnetically Modulated DDS (20)

PPTX
Presentation on Nanoparticles Smart Drug Delivery System For Cancer
PPTX
Nanotechnoloy in Cancer.pptx
PDF
nanoparticles (NPs).pdf
PPTX
Nanoscale drug delivery system
PDF
Targeted drug delivery system, Sem-VII, As per PCI Syllabus
PDF
Magnetic microspheres
PPTX
Drug targeting
PPTX
Magnetic microspheres
PPTX
Unit 3c CELLULAR NEVIGATION.pptx
PDF
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...
PDF
Nanomedicine: Targeted Drug Delivery Systems (www.kiu.ac.ug)
PDF
Nanomedicine
PPTX
Tumor Targeting
PPTX
Targeted drug delivery
PPTX
Targeted drug delivery system
PPT
site specific drug delivery system
PPTX
Targeted Drug Delivery System
DOCX
Drug targets
PPTX
Targeted drug delivery system
PDF
Nanoparticle Drug Delivery Systems for Cancer Treatment
Presentation on Nanoparticles Smart Drug Delivery System For Cancer
Nanotechnoloy in Cancer.pptx
nanoparticles (NPs).pdf
Nanoscale drug delivery system
Targeted drug delivery system, Sem-VII, As per PCI Syllabus
Magnetic microspheres
Drug targeting
Magnetic microspheres
Unit 3c CELLULAR NEVIGATION.pptx
An Overview of Active and Passive Targeting Strategies to Improve the Nano-Ca...
Nanomedicine: Targeted Drug Delivery Systems (www.kiu.ac.ug)
Nanomedicine
Tumor Targeting
Targeted drug delivery
Targeted drug delivery system
site specific drug delivery system
Targeted Drug Delivery System
Drug targets
Targeted drug delivery system
Nanoparticle Drug Delivery Systems for Cancer Treatment
Ad

More from Zulcaif Ahmad (20)

PPTX
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
PPTX
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
PPTX
Solubility & Method for determination of solubility
PDF
Autonomic Nervous System drugs classification
DOCX
Drug (Anti-Psychotic drug) Induce Parkinsonism
DOCX
Alcohol Induce Liver Injury
DOCX
Drug induce hepatitis
PPTX
Pulmonary hypertension
PPTX
Macrolides and lincosamide
PPTX
Chopramphenicol
PPTX
Immunosuppressants
PPT
Anthelmintics Pharmacology
PPT
Quinolones
PPTX
Cancer chemotherapy
PPTX
Asthma
PPTX
Evaporation presentation
PPTX
Audit community pharmacy
PPTX
Quality Management
PPTX
Dispensing of controlled substances
PPTX
Capsules
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
Solubility & Method for determination of solubility
Autonomic Nervous System drugs classification
Drug (Anti-Psychotic drug) Induce Parkinsonism
Alcohol Induce Liver Injury
Drug induce hepatitis
Pulmonary hypertension
Macrolides and lincosamide
Chopramphenicol
Immunosuppressants
Anthelmintics Pharmacology
Quinolones
Cancer chemotherapy
Asthma
Evaporation presentation
Audit community pharmacy
Quality Management
Dispensing of controlled substances
Capsules

Recently uploaded (20)

DOCX
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PPTX
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
PPTX
Acid Base Disorders educational power point.pptx
PDF
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
PPTX
Important Obstetric Emergency that must be recognised
PPTX
ACID BASE management, base deficit correction
PPTX
Neuropathic pain.ppt treatment managment
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PDF
Human Health And Disease hggyutgghg .pdf
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
PPT
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PDF
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
PPTX
Fundamentals of human energy transfer .pptx
PPTX
Slider: TOC sampling methods for cleaning validation
PPTX
Imaging of parasitic D. Case Discussions.pptx
PDF
CT Anatomy for Radiotherapy.pdf eryuioooop
DOCX
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
JUVENILE NASOPHARYNGEAL ANGIOFIBROMA.pptx
Acid Base Disorders educational power point.pptx
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
Important Obstetric Emergency that must be recognised
ACID BASE management, base deficit correction
Neuropathic pain.ppt treatment managment
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
Human Health And Disease hggyutgghg .pdf
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
Fundamentals of human energy transfer .pptx
Slider: TOC sampling methods for cleaning validation
Imaging of parasitic D. Case Discussions.pptx
CT Anatomy for Radiotherapy.pdf eryuioooop
NEET PG 2025 | Pharmacology Recall: 20 High-Yield Questions Simplified

Magnetically Modulated DDS

  • 1. Dr. Zulcaif Ahmad Ph.D. Scholar (Pharmaceutics) MPhil Pharmaceutics (Gold Medalist), Pharm.D (Gold Medalist)
  • 2. Magnetically Modulated Drug Delivery System (MMDDS)  Drug targeting is the delivery of the drugs to receptors or organs or any specific part of the body to which one wishes to deliver exclusively.  Magnetic Drug Targeting means the specific delivery of therapeutic agents to their desired target area using magnetic field, e.g. tumors by using magnetic nanoparticle (ferrofluids) bound to these agents and an external magnetic field which is focused on the tumor.  Magnetic fields are believed to be harmless to biological systems and adaptable to any part of the body.  Magnetic particles composed of magnetite (rock mineral and one of the main iron ores, with the chemical formula Fe3O4, Nickle, iron, cobolt and iron-boron etc) are well tolerated by body.
  • 3. Principles of magnetic targeting  In this technique, drug is bound to a magnetic compound , injected into a patient’s blood stream, and stopped with a powerful magnetic field in the target area.  Depending upon the type of drug , it is then slowly released from the magnetic carriers. Very high concentrations of chemotherapeutic or radiological agents can be achieved near the target site ,without any toxic effects to surrounding tissue or to the whole body.
  • 4. Principles of magnetic targeting MMDDS Drug / Carrier Target Tissue RES Organs (Liver, Spleen, Bone marrow) Mag.Drug/Carrier Phagocytosis Target Tissue
  • 5. Mechanism  Magnetic drug transport technique is based on the fact that the drug can be either encapsulated into a magnetic microsphere (or nanosphere) or conjugated on the surface of the micro/nanosphere.  When the magnetic carrier is intravenously administered, the accumulation take place within area to which the magnetic field is applied.  An external permanent magnetic field is applied on desired area to guide and concentrate the drugs.  Accumulation of the carrier at the target site allows them to deliver the drug locally.
  • 6. Physiological parameters that affect the MMDDS  Efficiency of accumulation of magnetic carrier depends on physiological parameters  Particle size  Surface characteristic  Field strength  Blood flow rate etc • This technique give us a major advantage that target the specific area and reduce the systemic distribution of drugs and result in effective treatment at lower doses.
  • 7. Concept of Magnetic Drug Targeting Magnet design: F= M ΔH, F is the force on particles, M is magnetic movement of particles, ΔH is magnetic field gradient.
  • 8. Magnetically Modulated Microcarriers  Following are the various magnetic carriers I. Magnetic microsphere II. Magnetic liposomes III. Magnetic nanoparticles IV. Magnetic Resealed Erythrocytes V. Magnetic Emulsion VI. Biomodulators VII. Magnetic neutrophils
  • 9. I) Magnetic Microsphere  Magnetic microspheres are supramolecular particles that are small enough to circulate through capillaries without producing embolic occlusion (<4 μm)  The loaded microspheres are introduced into a blood vessel, and in as little as half an hour, they gather at the target site by magnetic field of 0.5 – 0.8 tesla (T).  Magnetic microspheres were prepared by mainly two methods 1. Phase separation emulsion polymerization 2. Continuous solvent evaporation
  • 10. 1) Phase Separation emulsion Polymerization Fig 1.1. Formation of Magnetic Microsphere Dicloromethane (CH2Cl2) + Hexadecane (C16H34)
  • 11. 2) Continuous Phase Evaporation Fig 1.2. Formation of Magnetic Microsphere
  • 12. Evaluation Parameters  Particle size analysis  Surface topography  Texture  SEM  Drug entrapment efficiency  Percent magnetite content  In-vitro magnetic responsiveness  Drug release
  • 13. II) Magnetic liposomes  Liposomes are simple microscopic vesicles in which lipid bilayer structures are present with an aqueous volume entirely enclosed by a membrane, composed of lipid molecule.  There are a number of components present in liposomes with phospholipids and cholesterol being the main ingredients but in case of magneto liposomes magnetite is one of the components of the liposomes. Method of Preparation:  Generally these are magnetic carrier which can be prepared by entrapment of Ferro fluid within core of liposomes  Magneto liposome can also be produced by covalent attachment of ligands to the surface of the vehicles or by incorporation of target lipids in the matrix of structural phospholipids  Size range (80to 300 nm)
  • 14. Fig 1.3. Magnetic Liposomes DOX = Doxorubicin (Anti-cancer drug)
  • 15. III) Magnetic nanoparticles  Magnetic nanoparticles (MNPs) possess unique magnetic properties and the ability to function at the cellular and molecular level of biological interactions making them an attractive platform.  MNPs are now being developed for applications in the detection, diagnosis, and treatment of malignant tumors, cardiovascular disease, and neurological disease. Method of Preparation:  They can be synthesized using different methods like co- precipitation, thermal decomposition and micro emulsion method.  Size range (1 to 100 nm).
  • 16. Co-precipitation  The simultaneous precipitation of more than one compound from a solution.  Reactions involve the simultaneous occurrence of nucleation, growth, coarsening, and/or agglomeration processes. Fig 1.4. Magnetic nanoparticle
  • 17. IV) Magnetic Resealed Erythrocytes  Erythrocyte load with drug and magnetite using press well technique  Resealed erythrocytes have various advantages as drug carriers such as it is a) biodegradable b) Biocompatible c) Large quantity of variety of material can be encapsulated within small volume of cell. d) It can be utilized for organ targeting. Method of Preparation:  Magnetic resealed erythrocytes contains ferrofluides (magnetite) along with loaded drugs (Ibuprofen) within the cell.  The technique is based upon initial controlled swelling in a hypotonic buffered solution. This mixture is centrifuged. The supernatant is discarded and the cell fraction is brought to the lysis point by adding 100-120 liters portions of an aqueous solution of the drug to be encapsulated. The mixture is centrifuged. The tonicity of a cell mixture is restored at the lysis point by adding a calculated amount of hypertonic buffer (also called isotonic treatment).  Then, the cell suspension is incubated at 37oC to reanneal the resealed erythrocytes.
  • 18. Fig 1.6. Prevention of Arterial Thrombosis by Aspirin loaded Magnetic Resealed Erythrocytes. Fig 1.5. Magnetic resealed erythrocyte formation
  • 19. V) Magnetic Emulsion  Magnetic emulsion was also tried as drug carrier for chemotherapeutic agents. Method of Preparation:  The emulsion is magnetically responsive oil in water type of emulsion bearing a chemotherapeutic agent which could be selectively localized by applying an external magnetic field to specific target site.  Akimoto and Morimoto prepared magnetic emulsion by utilizing ethyl oleate based magnetic fluid as the dispersed phase, Casein solution as the continuous phase and anticancer agent, Methyl CCNU (Semustine) trapped in the oily dispersed phase as an active chemotherapeutic agent.  Methyl CCNU is a chloroethylnitrosourea
  • 20. Fig 1.7. Magnetic Emulsion
  • 21. VI) Biomodulators  Biological response modifiers (BMRs) alter host, tumor as well as microbial responses in four ways 1. Augmentation of host effectors mechanisms directed against tumor cells or micro organisms. 2. Decrease in host response that interferes with tumor resistance by a quantitative increase in endogenous effector resistance by an increase in endogenous effector molecules or redirecting their sites and duration of action. 3. Augmentation of tumor sensitivity to host cells by dedifferentiating tumor cells. 4. Increase in host tolerance of conventional cancer treatment.
  • 22.  There are basically two types of agents; Indirect and direct agents.  Indirect agents:  Include white cell chemo attractant, interleukins (1 to 4) and immunomodulator such as interferon(α , β and γ).  Direct agents:  Antibodies, lymphotoxin and tumor necrosis factor (TNF, also called Cachetin).
  • 23. VII) Magnetic neutrophils  Indirect approach of targeting white cells by chemo attraction fails. Even though failure of chemotaxis is not observed in all patients, such conditions are life threatening.  Making neutrophils ingest magnetite base system ought to be developed, so that the sites of severe infection can be selectively approached for therapy.
  • 24. APPLICATIONS  Some of the application of magnetically modulated drug targeting especially tumor targeting along with some other application are 1. Magnetic systems for the therapy of diseases. 2. Magnetic delivery of chemotherapeutic drugs to liver tumors. 3. Magnetic targeting of radioactivity. 4. Treatment of tumors with magnetically induced hyperthermia. 5. Other magnetic targeting applications. 6. Magnetic control of pharmacokinetic parameters and drug release.  Magnetic systems for the diagnosis of diseases.  Magnetic systems for magnetic cell separation.
  • 26. CONCLUSION  Magnetic Drug targeting is efficient & novel approach of drug targeting.  Larger amount of freely circulating drug can be replaced by smaller amount of magnetically targeted drug.  It is a challenging area for future research in the drug targeting.  More researches, long term toxicity study, and characterization will ensure the improvement of magnetic drug delivery system.

Editor's Notes

  • #11: Hexadecane, PS(Polymer Solution)
  • #16: The simultaneous precipitation of more than one compound from a solution.
  • #18: The ligand is usually a molecule which produces a signal by binding to a site on a target protein
  • #22: Def: That modify the biological response